Skip to main content

Edwards Lifesciences Corp stock price and financials

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.15+1.28%Close 13 Nov 2026
Market value
$61.47B
P/E
60.19
EV / EBITDA
35.87
Beta · 1 year
0.54
Return · 1 year
+25.2%
52-week range$74.66 — $107.69

Share price close 16 Nov 2026

+21.6%1 monthHigh $107.15Low $86.60
$80$90$100$110Q3 FY2026 report filed 4 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+31.6%6 monthsHigh $107.15Low $82.16
$80$90$100$110Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 4 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+25.7%year to dateHigh $107.15Low $75.87
$70$80$90$100$110Q4 FY2025 report filed 25 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 4 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+24.1%1 yearHigh $107.15Low $75.87
$70$80$90$100$110Q4 FY2025 report filed 25 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 4 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+59.9%3 yearsHigh $107.15Low $59.70
$40$60$80$100$120Q4 FY2023 report filed 12 Feb 2024Q1 FY2024 report filed 29 Apr 2024Q2 FY2024 report filed 31 Jul 2024Q3 FY2024 report filed 6 Nov 2024Q4 FY2024 report filed 28 Feb 2025Q1 FY2025 report filed 6 May 2025Q2 FY2025 report filed 6 Aug 2025Q3 FY2025 report filed 5 Nov 2025Q4 FY2025 report filed 25 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 4 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+261%10 yearsHigh $129.55Low $27.78
$0$50$100$150Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Edwards Lifesciences Corp reported revenue of $6.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 11.5% from fiscal 2024. Net income was $1.07 billion and diluted earnings per share $1.83.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.72 billion, up 10.5% from a year earlier.

Figures from Edwards Lifesciences Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026.

Against Health Care

Growth
Lower half
Revenue +6.7% a year over five years · 21st of 37
Profitability
Top quarter
Return on invested capital 19.7%, five-year average · 6th of 38
Balance sheet
Top quarter
More cash than debt · 5th of 38
Valuation
Dearer than most
P/E 60.2 · 32nd of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$6.07B+11.5%
Net income
$1.07B−74.3%
Diluted EPS
$1.83−73.7%
Gross margin
78.0%−1.4 pts
Free cash flow
$1.33B+361%
Net cash
$3.52B

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$2B$4B$6B$8BRevenue, FY16: $2.96BNet income, FY16: $569.5MFY16Revenue, FY17: $3.44BNet income, FY17: $583.6MFY17Revenue, FY18: $3.72BNet income, FY18: $722.2MFY18Revenue, FY19: $4.35BNet income, FY19: $1.05BFY19Revenue, FY20: $4.39BNet income, FY20: $823.4MFY20Revenue, FY21: $5.23BNet income, FY21: $1.5BFY21Revenue, FY22: $4.46BNet income, FY22: $1.52BFY22Revenue, FY23: $5.01BNet income, FY23: $1.4BFY23Revenue, FY24: $5.44BNet income, FY24: $4.17BFY24Revenue, FY25: $6.07BNet income, FY25: $1.07BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 4 Nov 2026 · Full results →

Revenue
$1.72B+10.5% on a year
Gross margin
78.5%+0.7 pts on a year
Operating income
$299.1M−2.6% on a year
Net income
$307.5M+5.6% on a year
Diluted EPS
$0.53+6.0% on a year
Free cash flow
$506.7M−1.8% on a year

Comparable companies All of Health Care →

Edwards Lifesciences Corp beside the other S&P 500 members in Health Care Equipment, by market value.

Edwards Lifesciences Corp and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2
GE HealthCareGEHC$37.71B+1.4%+10.7%+6.9%10.0%17.5

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%78.0%20.8%17.7%FY16FY19FY22FY25

Edwards Lifesciences Corp revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By region

Edwards Lifesciences Corp revenue by region, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025
United States$2.63B$2.95B+12.2%$3.21B+8.8%$3.54B+10.5%
Europe$1.04B$1.18B+13.4%$1.32B+12.0%$1.52B+14.8%
Rest of World$436.0M$531.1M+21.8%$572.0M+7.7%$652.3M+14.0%
Japan$359.5M$350.8M−2.4%$339.8M−3.1%$354.7M+4.4%
Total revenue$4.46B$5.01B$5.44B$6.07B

By product

Edwards Lifesciences Corp revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025
Transcatheter Aortic Valve Replacement$3.52B$3.88B+10.3%$4.11B+5.8%$4.49B+9.3%
Surgical$829.7M$932.6M+12.4%$981.3M+5.2%$1.03B+4.9%
Transcatheter Mitral and Tricuspid Therapies$116.1M$197.6M+70.2%$352.1M+78.2%$550.6M+56.4%
Total revenue$4.46B$5.01B$5.44B$6.07B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Edwards Lifesciences Corp income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$2.96B$3.44B$3.72B$4.35B$4.39B$5.23B$4.46B$5.01B$5.44B$6.07B
Revenue growth+18.8%+15.9%+8.4%+16.8%+0.9%+19.3%−14.7%+12.2%+8.6%+11.5%
Gross profit$2.17B$2.56B$2.78B$3.23B$3.31B$3.98B$3.74B$4.03B$4.32B$4.73B
Operating income$751.2M$1.09B$748.2M$1.15B$897.6M$1.69B$1.50B$1.31B$1.38B$1.26B
Net income$569.5M$583.6M$722.2M$1.05B$823.4M$1.50B$1.52B$1.40B$4.17B$1.07B
Diluted EPS$0.87$0.90$1.13$1.64$1.30$2.38$2.44$2.30$6.97$1.83
Gross margin73.1%74.5%74.8%74.4%75.4%76.1%83.8%80.5%79.5%78.0%
Operating margin25.3%31.7%20.1%26.4%20.5%32.3%33.6%26.1%25.3%20.8%
Net margin19.2%17.0%19.4%24.1%18.8%28.7%34.1%28.0%76.7%17.7%

Cash flow

Edwards Lifesciences Corp cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$704.4M$1.00B$926.7M$1.18B$1.05B$1.73B$1.22B$895.8M$542.3M$1.60B
Capital expenditure$176.1M$168.1M$238.7M$254.4M$407.0M$325.8M$244.6M$253.0M$252.4M$260.2M
Free cash flow$528.3M$832.6M$688.0M$928.5M$647.3M$1.41B$973.6M$642.8M$289.9M$1.33B

Balance sheet and shares

Edwards Lifesciences Corp balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$930.1M$818.3M$714.1M$1.18B$1.18B$862.8M$769.0M$1.13B$3.05B$2.94B
Total debt$822.3M$1.04B$593.8M$678.8M$694.9M$690.3M$691.3M$685.1M$700.0M$705.4M
Shareholders' equity$2.62B$2.96B$3.14B$4.15B$4.57B$5.84B$5.81B$6.65B$10.00B$10.34B
Diluted shares653M648M641M637M632M631M624M609M599M586M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Edwards Lifesciences Corp quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.39B$1.41B$1.53B$1.55B$1.57B$1.65B$1.74B$1.72B
Revenue, year on year+9.4%+6.2%+11.9%+14.7%+13.3%+16.7%+13.6%+10.5%
Gross margin78.9%78.7%77.5%77.8%78.1%78.0%77.5%78.5%
Operating income$312.6M$394.8M$411.2M$307.1M$151.1M$477.6M$513.2M$299.1M
Net income$385.6M$358.0M$333.2M$291.1M$91.20M$380.7M$241.9M$307.5M
Diluted EPS$0.65$0.61$0.56$0.50$0.16$0.66$0.42$0.53
Free cash flow−$177.3M$224.4M$240.9M$516.2M$353.5M−$21.10M$585.0M$506.7M

Operating KPIs

The operating figures Edwards Lifesciences Corp reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Edwards Lifesciences Corp operating KPIs
KPILatestPeriodChange on a yearRecent periods
Transcatheter Aortic Valve Replacement revenue$1.2Bquarter to 30 Sep 2026up 8.0%
Surgical revenue$264.4Mquarter to 30 Sep 2026up 2.5%
Transcatheter Mitral and Tricuspid Therapies revenue$209.5Mquarter to 30 Sep 2026up 44.3%
United States revenue$1.0Bquarter to 30 Sep 2026up 11.0%
Europe revenue$414.6Mquarter to 30 Sep 2026up 6.9%
Rest of World revenue$201.3Mquarter to 30 Sep 2026up 20.1%
Japan revenue$92.0Mquarter to 30 Sep 2026up 2.1%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Edwards Lifesciences Corp's revenue in fiscal 2025?

$6.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Edwards Lifesciences Corp's net income in fiscal 2025?

$1.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Edwards Lifesciences Corp's diluted earnings per share in fiscal 2025?

$1.83 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Edwards Lifesciences Corp's gross margin?

78.0% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Edwards Lifesciences Corp's operating margin?

20.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Edwards Lifesciences Corp generate in fiscal 2025?

$1.33 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Edwards Lifesciences Corp's revenue come from?

In fiscal 2025, by region: United States $3.54B (58%), Europe $1.52B (25%), Rest of World $652.3M (11%), Japan $354.7M (5.8%), out of $6.07B in all, as stated in its annual report.

In the terminal

Twenty years of Edwards Lifesciences Corp's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans